Baxter International Inc. (NYSE:BAX) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, July 26th. Analysts expect Baxter International to post earnings of $0.56 per share for the quarter. Baxter International has set its Q2 guidance at $0.55-$0.57 EPS and its FY17 guidance at $2.20-$2.28 EPS.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, April 26th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. Baxter International had a net margin of 18.09% and a return on equity of 14.03%. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.43 billion. During the same period in the prior year, the company posted $0.36 EPS. The company’s revenue was up 4.2% compared to the same quarter last year. On average, analysts expect Baxter International to post $2.27 EPS for the current fiscal year and $2.58 EPS for the next fiscal year.

Baxter International Inc. (NYSE BAX) opened at 62.14 on Wednesday. The firm’s 50-day moving average is $60.04 and its 200-day moving average is $53.67. The firm has a market capitalization of $33.78 billion, a P/E ratio of 18.39 and a beta of 0.66. Baxter International Inc. has a 52-week low of $43.13 and a 52-week high of $62.49.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 2nd. Shareholders of record on Friday, September 1st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 1.03%. Baxter International’s dividend payout ratio is presently 19.05%.

Several research firms have recently weighed in on BAX. Royal Bank Of Canada boosted their price target on Baxter International from $55.00 to $58.00 and gave the stock a “sector perform” rating in a report on Thursday, April 27th. BMO Capital Markets restated a “hold” rating and set a $55.00 price target on shares of Baxter International in a report on Thursday, April 27th. Zacks Investment Research cut Baxter International from a “hold” rating to a “sell” rating in a report on Wednesday, April 5th. Cantor Fitzgerald began coverage on Baxter International in a report on Thursday, June 29th. They set an “overweight” rating and a $70.00 price target on the stock. Finally, Barclays PLC boosted their price target on Baxter International from $62.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Baxter International has a consensus rating of “Buy” and a consensus target price of $61.54.

In other Baxter International news, Director Carole J. Shapazian sold 3,760 shares of the business’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $55.89, for a total value of $210,146.40. Following the transaction, the director now directly owns 16,226 shares of the company’s stock, valued at $906,871.14. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Brik V. Eyre sold 130,732 shares of the business’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $55.69, for a total value of $7,280,465.08. Following the completion of the transaction, the senior vice president now directly owns 49,966 shares in the company, valued at $2,782,606.54. The disclosure for this sale can be found here. Over the last three months, insiders sold 137,110 shares of company stock worth $7,642,246. Insiders own 0.05% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Baxter International Inc. (BAX) Set to Announce Quarterly Earnings on Wednesday” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Earnings History for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with's FREE daily email newsletter.